Page last updated: 2024-10-27

glimepiride and Aging

glimepiride has been researched along with Aging in 3 studies

glimepiride: structure given in first source

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
" Safety endpoints were adverse events including hypoglycaemia."2.84Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial). ( Ishida, H; Kitaoka, M; Ohsugi, M; Satoh, J; Seino, Y; Shihara, N; Terauchi, Y; Yabe, D; Yamada, Y, 2017)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Lietzau, G1
Magni, G1
Kehr, J1
Yoshitake, T1
Candeias, E1
Duarte, AI1
Pettersson, H1
Skogsberg, J1
Abbracchio, MP1
Klein, T1
Nyström, T1
Ceruti, S1
Darsalia, V1
Patrone, C1
Terauchi, Y1
Yamada, Y1
Ishida, H1
Ohsugi, M1
Kitaoka, M1
Satoh, J1
Yabe, D1
Shihara, N1
Seino, Y1
Maeda, T1
Oyama, J1
Higuchi, Y1
Koyanagi, M1
Sasaki, M1
Arima, T1
Mimori, K1
Makino, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety Comparison of Sitagliptin and Glimepiride in Elderly Japanese Patients With Type 2 Diabetes[NCT01183104]305 participants (Actual)Interventional2010-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Body Weight at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionkg (Mean)
Sitagliptin-0.367
Glimepiride0.309

Change From Baseline in HbA1c at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionpercent (Least Squares Mean)
Sitagliptin-0.66
Glimepiride-0.77

Change From Baseline in HOMA-β at 52 W

β cell function is measured by the Homeostatic Model Assessment(HOMA-β). HOMA β = [20 x fasting insulin (μU/mL)] / [fasting plasma glucose (mmol/L) - 3.5] (NCT01183104)
Timeframe: Baseline and 52 W

Interventionpercent (Mean)
Sitagliptin10.2
Glimepiride23.7

Change From Baseline in Insulin/Proinsulin Ratio at 52 W

(NCT01183104)
Timeframe: Baseline and 52 W

Interventionratio (Mean)
Sitagliptin-0.049
Glimepiride-0.002

Number of Participants With Hypoglycaemia

(NCT01183104)
Timeframe: From baseline to 52 W

InterventionParticipants (Count of Participants)
Sitagliptin7
Glimepiride23

The Number of Participants Achieving HbA1c < 6.9 %

(NCT01183104)
Timeframe: 52 W

InterventionParticipants (Count of Participants)
Sitagliptin89
Glimepiride86

Trials

1 trial available for glimepiride and Aging

ArticleYear
Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
    Diabetes, obesity & metabolism, 2017, Volume: 19, Issue:8

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Blood Glucose Self-Monitoring; Diabetes

2017

Other Studies

2 other studies available for glimepiride and Aging

ArticleYear
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
    Neurobiology of aging, 2020, Volume: 89

    Topics: Aging; Animals; Corpus Striatum; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dise

2020
The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.
    The aging male : the official journal of the International Society for the Study of the Aging Male, 2011, Volume: 14, Issue:1

    Topics: Aged; Aged, 80 and over; Aging; Bilirubin; Clinical Laboratory Techniques; Creatine Kinase; Diabetes

2011